{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T01:40:22Z","timestamp":1720662022175},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Depending on a variety of prognostic factors including age, stage, laboratory abnormalities, and initial response to treatment, from 70% to 90% of patients with advanced-stage Hodgkin lymphoma can be cured with modern multiagent chemotherapy. Two effective strategies offer the promise to improve on those results. Early intensification of treatment, typically by increasing the doses and frequency of administration of standard chemotherapy agents, induces higher initial response rates but has the major drawback of causing unacceptably severe acute toxicity, increased numbers of secondary neoplasms, and infertility due to oligospermia in men and premature menopause in women. Alternatively, integration of novel therapeutic agents into primary treatment is attractive, especially when the introduction not only improves the frequency and durability of disease response but also does not unacceptably increase acute or long-term toxicity. Finally, widespread availability of functional imaging with positron emission tomography now enables response-adapted therapy, a separate innovation in the treatment of Hodgkin lymphoma that can be incorporated with either intensified chemotherapy or addition of novel agents. This article discusses these exciting new developments in the treatment of advanced-stage Hodgkin lymphoma.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000333","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T09:55:42Z","timestamp":1538646942000},"page":"230-236","source":"Crossref","is-referenced-by-count":3,"title":["Advanced-Stage Hodgkin Lymphoma"],"prefix":"10.1097","volume":"24","author":[{"given":"Joseph M.","family":"Connors","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","year":"1989","journal-title":"J Clin Oncol"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJM198506203122504","article-title":"The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer","volume":"312","year":"1985","journal-title":"N Engl J Med"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","year":"1975","journal-title":"Cancer"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2014-07-537480","article-title":"Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose\u2013positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdv077","article-title":"Phase II study of interim PET-CT\u2013guided response-adapted therapy in advanced Hodgkin's lymphoma","volume":"26","year":"2015","journal-title":"Ann Oncol"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","year":"2007","journal-title":"J Clin Oncol"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","year":"2006","journal-title":"Blood"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","year":"2014","journal-title":"Haematologica"},{"key":"bib15-20230924","article-title":"BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD12- trials of the German Hodgkin Study Group (GHSG)","volume":"104","year":"2004","journal-title":"Blood"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","year":"2003","journal-title":"N Engl J Med"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","article-title":"Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"bib20-20230924","first-page":"2790","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","year":"2018","journal-title":"Lancet"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles >\/= 4 baseline): final results in stage III\u2013IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial","volume":"25","year":"2014","journal-title":"Ann Oncol"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score >\/= 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdp271","article-title":"Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET\/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma","volume":"21","year":"2010","journal-title":"Ann Oncol"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/annonc\/mdu387","article-title":"Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"25","year":"2014","journal-title":"Ann Oncol"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1200\/JCO.2017.72.7925","article-title":"Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.bbmt.2015.11.315","article-title":"Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse","volume":"22","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","year":"2010","journal-title":"Am J Hematol"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib37-20230924","first-page":"1588","article-title":"Safety and efficacy of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed\/refractory hodgkin and non-Hodgkin lymphoma","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V124.21.806.806","article-title":"Novel chimeric antigen receptor T cells for the treatment of Hodgkin lymphoma","volume":"124","year":"2014","journal-title":"Blood"},{"issue":"(Suppl 1)","key":"bib42-20230924","first-page":"653","article-title":"Pilot study of non-viral, RNA-redirected autologous anti-CD19 chimeric antigen receptor modified T-cells in patients with refractory\/relapsed Hodgkin lymphoma (HL)","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1\u2013associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2326-6066.CIR-17-0325","article-title":"Complex immune evasion strategies in classical hodgkin lymphoma","volume":"5","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","year":"2012","journal-title":"Clin Cancer Res"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130404-201809000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:49:02Z","timestamp":1720658942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201809000-00005"}},"subtitle":["New Approaches Based on Novel Therapeutic Agents or Treatment Intensification"],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000333","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}